We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 701 for:    translate

Treating to Reduce Albuminuria and Normalize Hemodynamic Function in Focal ScLerosis With dApagliflozin Trial Effects (TRANSLATE)

This study is currently recruiting participants.
Verified May 2017 by David Z.I. Cherney, University Health Network, Toronto
Sponsor:
ClinicalTrials.gov Identifier:
NCT02585804
First Posted: October 23, 2015
Last Update Posted: May 23, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Collaborators:
AstraZeneca
University of Toronto
Toronto General Hospital
Information provided by (Responsible Party):
David Z.I. Cherney, University Health Network, Toronto
October 22, 2015
October 23, 2015
May 23, 2017
September 2015
September 2017   (Final data collection date for primary outcome measure)
The change in Glomerular Filtration Rate (GFR) After an 8 week treatment with dapagliflozin [ Time Frame: Before and after an 8 week treatment with dapagliflozin ]
Glomerular Filtration Rate (GFR, based on plasma inulin clearance) will be measured at baseline and after 8 weeks of treatment.
Same as current
Complete list of historical versions of study NCT02585804 on ClinicalTrials.gov Archive Site
  • The change in Effective Renal Plasma Flow (ERPF) After an 8 week treatment with dapagliflozin [ Time Frame: Before and after an 8 week treatment with dapagliflozin ]
    Effective Renal Plasma Flow (ERPF, based on paraaminohippurate plasma clearance) will be measured at baseline and after 8 weeks of treatment.
  • The change in Blood Pressure After an 8 week treatment with dapagliflozin [ Time Frame: Before and after 8 weeks of treatment with dapagliflozin ]
  • The change in albuminuria after 8 weeks of treatment with dapagliflozin [ Time Frame: Before and after 8 weeks of treatment with dapagliflozin ]
  • The change in urinary vasoactive mediators after 8 weeks of treatment with dapagliflozin [ Time Frame: Before and after 8 weeks of treatment with dapagliflozin ]
Same as current
Not Provided
Not Provided
 
Treating to Reduce Albuminuria and Normalize Hemodynamic Function in Focal ScLerosis With dApagliflozin Trial Effects
Treating to Reduce Albuminuria and Normalize Hemodynamic Function in Focal ScLerosis With dApagliflozin Trial Effects: "The TRANSLATE Study"
Patients with Focal Segmental Glomerulosclerosis (FSGS) constitute an increasing proportion of the total glomerulonephritis (GN) patient cohort in North America while FSGS is a risk factor for end stage renal failure. Current non-immunological FSGS therapies include the use of angiotensin converting enzyme inhibitors (ACEi) or angiotensin II receptor blockers (ARB), to reduce intraglomerular hypertension. Unfortunately, these agents lead to incomplete renal protection. The aim of the current study is to determine whether the addition of novel sodium glucose cotransport-2 inhibitors (SGLT2i) to standard of care leads to reduced intraglomerular pressure and suppression of proteinuria. We hypothesize that combination therapy of SGLT2i drugs and conventional RAASi results in additive renal protective effects in FSGS patients. A further goal is to examine mechanisms of SGLT2 inhibition by measuring renal hemodynamic function and sodium handling. Kidney function will be assessed in FSGS patients before and after an 8 week treatment with SGLT2i dapagliflozin.
FSGS and diabetic nephropathy may have common pathogenic mechanisms, that are mediated by intraglomerular hypertension, leading to hyperfiltration and proteinuria. Given that SGLT2i corrects early hemodynamic abnormalities in patients with diabetes, our aim is to determine if a similar benefit may extend to patients with FSGS. Based on previous experimental and clinical data, we hypothesize that SGLT2i will improve renal hemodynamic abnormalities characteristic of FSGS that promote renal injury and proteinuria.
Interventional
Phase 4
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Focal Segmental Glomerulosclerosis
Drug: Dapagliflozin
Oral tablet, 10mg, PO, 8 weeks
Other Name: Trade name Farxiga®
Experimental: Dapagliflozin (trade name Farxiga®)
Oral tablet, 10mg, PO, 8 weeks
Intervention: Drug: Dapagliflozin
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
12
September 2017
September 2017   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male or female subjects diagnosed with FSGS ≥1 month prior to informed consent
  • eGFR≥45 ml/min/1.73m2
  • Age 18 years or greater
  • No history of diabetes
  • Body Mass Index (BMI) 18.5 - 45.0 kg/ m2
  • Blood pressure ≥ 100/60 at screening
  • Stable therapy with either an ACEi or angiotensin II receptor blocker or direct renin inhibitor for > 1 month
  • >30 mg/day and <6 g/day of proteinuria unless the patient is not a candidate for immunosuppressive therapy

Exclusion Criteria:

  • Leukocyte and/or nitrite positive urinalysis that is untreated;
  • History of organ transplantation, cancer, liver disease;
  • Bariatric surgery or other gastrointestinal surgeries that induce chronic malabsorption within the past two years;
  • Current treatment with systemic corticosteroids, calcineurin inhibitors, or other immunosuppressant medications;
  • Blood dyscrasias or any disorders causing hemolysis or unstable red blood cells;
  • Pre-menopausal women who are nursing, pregnant, or of child-bearing potential and not practising an acceptable method of birth control;
  • Participation in another therapeutic trial with an investigational drug within 30 days prior to informed consent;
  • Alcohol or drug abuse within three months prior to informed consent that would interfere with trial participation or any ongoing clinical condition that would jeopardize subject safety or study compliance based on investigator judgement;
  • Liver disease, defined by serum levels of alanine transaminase, aspartate transaminase, or alkaline phosphatase >3 x upper limit of normal as determined during screening;
  • Cardiac, lung or peripheral vascular disease or stroke;
  • Pancreas, pancreatic islet cells or renal transplant recipient;
  • Medical history of cancer or treatment for cancer in the last five years prior to screening;
  • History of allergy or angioedema with RAAS inhibitor exposure;
  • Kidney disease due primarily to another condition aside from FSGS;
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact: Vesta Lai, RN 416-340-4800 ext 8508 vesta.lai@uhn.ca
Contact: Harindra Rajasekeran, HBSc harindra.rajasekeran@utoronto.ca
Canada
 
 
NCT02585804
REB# 14-8284-B
No
Not Provided
Not Provided
David Z.I. Cherney, University Health Network, Toronto
University Health Network, Toronto
  • AstraZeneca
  • University of Toronto
  • Toronto General Hospital
Not Provided
University Health Network, Toronto
May 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP